Springworks Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
SpringWorks Therapeutics reports a significant increase in product revenue for Q1 2025, driven by sales of OGSIVEO and GOMEKLI, while also announcing a pending acquisition by Merck KGaA.
SpringWorks Therapeutics reported $49.3 million in product revenue for the third quarter of 2024, driven by sales of OGSIVEO, and is progressing its pipeline with regulatory submissions for mirdametinib.
SpringWorks Therapeutics reported a net product revenue of $40.2 million for the second quarter of 2024, driven by the commercial launch of OGSIVEO.
SpringWorks Therapeutics reported $21.0 million in net product revenue from OGSIVEO sales in the first quarter of 2024, marking its first commercial revenue.